Company intelligence / Profile preview

Omniose

St. Louis, Missouri, United Statesomniose.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Omniose has demonstrated the ability to generate high-quality bioconjugate vaccines using its proprietary platform. The company has received significant grant funding ($11.8M from NIAID) for vaccine development against multiple bacterial pathogens and recently entered an exclusive collaboration with AstraZeneca for up to three years targeting new bacterial vaccine candidates. No published clinical results yet.

Therapeutic areas: Infectious Diseases
Modalities: Polysaccharide conjugate vaccines
Industry: Biotech

Drug pipeline

4 assets

klebsiella polyvalent vaccine

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

AstraZenecaNational Institute of Allergy and Infectious Diseases (NIAID)

Beyond the preview

Go deeper on Omniose.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omniose.

Explore the full profile